Funding:
Research support was provided by the US Department of Veterans Affairs, the National Center for PTSD, the NIMH (R01MH112668), The Brain and Behavior Foundation, the NY Women’s Committee, the Robert E. Leet and Clara M. Guthrie Patterson Trust, the American Foundation for Suicide Prevention, VA Career Development Award #IK2CX001873 and the Beth K and Stuart Yudofsky Chair in the Neuropsychiatry of Military Post Traumatic Stress Syndrome. The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors, the Department of Veterans Affairs, NIH, or the U.S. Government. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Acknowledgments:
The authors would like to thank the patients who participated in this study for their invaluable contributions. We also thank the staff members who have rotated through the Emerge Research Program during the course of this study.
Data Availability:
Data available upon reasonable request and following completion of a data use agreement limiting the use of shared data and prohibiting re-identification of subjects.
Author Contributions:
CLA: Conceptualization, Formal Analysis, Writing-Original Draft, Writing-Review and editing, Project Administration, Visualization, Data Curation. LAA: Writing-Original Draft, Writing-Review and editing, Supervision, Funding Acquisition. TJA: Writing-Review and editing, Methodology, Software. SF: Writing-Review and editing, Investigation. JHK: Writing-Review and editing, Funding Acquisition, Supervision. CGA: Conceptualization, Methodology, Software, Formal Analysis, Visualization, Writing-Review and editing, Funding Acquisition, Supervision.
Additional Information:
Dr. Abdallah has served as a consultant, speaker and/or on advisory boards for Genentech, Janssen, Lundbeck, FSV7 and Aptinyx, and editor of Chronic Stress for Sage Publications, Inc.; Filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (filed on Aug 20, 2018). Dr. Krystal is a consultant for AbbVie, Inc., Amgen, Astellas Pharma Global Development, Inc., AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Inc., Neurovance, Inc., FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Inc., Sage Therapeutics, Inc., Sunovion Pharmaceuticals, Inc., and Takeda Industries; is on the Scientific Advisory Board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc., Naurex, Inc., and Pfizer; is a stockholder in Biohaven Pharmaceuticals; holds stock options in Mnemosyne Pharmaceuticals, Inc.; holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, U.S. Patent No. 5,447,948 (issued Sep 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, U.S. Patent No. 8,778,979 (issued Jul 15, 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression – U.S. Application No. 14/197,767 (filed on Mar 5, 2014); U.S. application or Patent Cooperation Treaty international application No. 14/306,382 (filed on Jun 17, 2014). Filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (filed on Aug 20, 2018). Dr. L. Averill has served as a consultant, speaker and/or on advisory boards for Transcend Therapeutics, Beond, Reason for Hope, Source Research Foundation, Guidepoint, Techspert, the Cohen Foundation, and owns NPSYT, PLLC. All other co-authors declare no conflict of interest.